Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: full-pipeline trial registry
A small indexed set (2 trials) with no open enrollment listed right now.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · none currently recruiting · #7,188 of 28,707 conditions by registered trial count
Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: 2 US clinical trials tracked, none currently recruiting.
Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma is the subject of 2 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 1 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is University of California, San Diego, running 1 of these trials.
Enrollment posture brief
Registry condition chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma
OPEN 0 | RECR 0% | LATE 1 | EARLY 1 | RANK #7188 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma has no open enrollment in this registry pull (2 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma is recruiting below its size-band peers.
0 of 2 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Indexed trials (enrollment closed)
2 total, page 1 of 1
A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
AstraZeneca
NCT05057494
Rituximab + High-Dose Methylprednisolone Debulking Prior to Venetoclax for CLL & SLL Patients
University of California, San Diego
NCT04981912
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma page
2 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- University of California, San Diego sponsors the most Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma trials on record, review their full trial history before evaluating a specific study. See University of California, San Diego's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma condition card totals 2 registered trials; most-linked intervention HDMP + rituximab as a means of debulking prior to initiating venetoclax.; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.